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Abstract
Background: Cardiovascular diseases (CVD) in diabetic patients have endothelial dysfunction as a key pathogenetic
event. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), plays a
pivotal role in endothelial dysfunction. Different natural polyphenols have been shown to preserve endothelial
function and prevent CVD. In this study, we assessed the effect of silibinin, a widely used flavonolignan from milk
thistle, on ADMA levels and endothelial dysfunction in db/db mice.
Methods: Eight-week-old db/db mice were administrated a 20 mg/Kg i.p. daily dose of silibinin (n = 6) or vehicle
(n = 6) for four weeks. Heterozygous lean db/m mice served as control. Plasma, aorta and liver ADMA levels were
determined by ELISA. Vascular reactivity to phenilephrine (PE), acetylcholine (ACh), sodium nitroprusside (SNP) and
ADMA was assessed in isolated aortic segments, in wire myograph.
Results: Plasma and aorta ADMA levels were higher in db/db than in control lean mice. Silibinin administration
markedly decreased plasma ADMA; consistently, aorta ADMA was reduced in silibinin-treated animals. Plasma and
aorta ADMA levels exhibited a positive correlation, whereas liver ADMA was inversely correlated with both plasma
and aorta ADMA concentrations. Endothelium-(NO)-dependent vasodilatation to ACh was impaired in db/db mice
and was restored in the silibinin group, in accordance with the observed reduction of plasma and vascular levels
of ADMA. Endothelium-independent vasodilatation to SNP was not modified by silibinin administration; contractile
tone induced in isolated aorta from db/db mice by challenging with exogenous ADMA was not affected by the
treatment.
Conclusions: Silibinin markedly improves endothelial dysfunction in db/db mice by reducing circulating and
vascular ADMA levels. Clinical studies are warranted to assess the efficacy of silibinin for cardiovascular protection.
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Background
Cardiovascular diseases (CVD) are a leading cause of
death worldwide and are tightly related to obesity, dia-
betes and the full spectrum of the metabolic syndrome
[1]. Endothelial dysfunction is a main event in the
pathogenetic cascade conducing to cardiovascular events
[2] and therapies aiming at preserving endothelium are
needed for the effective prevention of CVD. Endothe-
lium plays a central role in the physiological mainte-
nance of vascular function by regulating vascular tone,
leukocyte adhesion and platelet activation, as a result of
release of vasoactive substances such as nitric oxide
(NO), prostacyclin and endothelin [3].
Several natural polyphenols have been evaluated for
their ability to preserve endothelial function and thus
for their effectiveness in preventing CVD [4]. Recently,
silibinin, a polyphenolic compound contained in sily-
marin, has been demonstrated to exert in vitro protec-
tive effects on endothelial cells [5]; however, it is not
clear whether silibinin may exert vascular protective
effect in vivo.
In the diabetic status, vascular dysfunction is mainly
related to decreased NO bioavailability [6]. Previous stu-
dies showed that endogenous arginine analogs may play
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metric N
G,N
G-dimethyl-L-arginine (ADMA) is an endo-
genous inhibitor of all isoforms of Nitric Oxide Synthase
(NOS). Several evidences suggest that ADMA exerts
deleterious vascular effects by inhibiting endothelial
NOS (eNOS). Elevated ADMA levels have been identi-
fied as a biomarker of endothelial dysfunction [8]. Inter-
estingly, circulating ADMA is significantly correlated
with carotid artery intima-media thickness [9], and
ADMA increase precedes the occurrence of vascular
occlusive disease [10]. Taken together, these observa-
tions suggest that plasma ADMA is significantly asso-
ciated with cardiovascular risk. ADMA metabolism is
related to its generation from protein breakdown and to
its cleavage by dimethylarginine hydrolase (DDAH) into
citrulline and dimethylamine [11].
The liver is a main regulator of circulating ADMA
levels [12]. Nijvedt documented a daily hepatic ADMA
extraction for more than seven hundred times the
amount of plasma ADMA in rats [13]. Serum ADMA is
increased in patients with diabetes [14] and in non-dia-
betic insulin-resistant subjects [15,16], and improvement
in insulin resistance is associated to a decrease of
ADMA [17,18]. Animal models of diabetes, such as db/
db mice, are widely studied because they reproduce sev-
eral metabolic and vascular alterations occurring in
humans; endothelial dysfunction has been documented
in db/db mice [19-24], however, to the best of our
knowledge, the association of ADMA levels with
endothelial dysfunction has not been investigated in this
animal model. In this study we assessed plasma, aorta
and liver ADMA levels and analyzed endothelium-
dependent vascular reactivity in db/db mice; further-
more, we examined the effects of silibinin administra-
tion on these parameters.
Methods
Animals and treatments
All procedures were carried out in accordance with the
Italian Guidelines for the Care and Use of Laboratory
Animals and with the ARRIVE guidelines [25]. Eight-
week-old male BKS.Cg-m+/+ Leprdb/J (db/db) obese
mice and eight-week-old male heterozygous db/m lean
control mice were purchased from Charles River Lab
(Calco, Italy). Animals were housed at constant room
temperature (23°C) (n = 3 per cage) under 12 hours
light/dark cycles with ad libitum access to water and
were fed a standard diet. Silibinin dihydrogen disucci-
nate disodium (Madaus, Köln, Germany) was dissolved
in saline which was also used as vehicle for the placebo-
treated animals. Eighteen mice were distributed in 3
groups: group I (db/m + vehicle) included six heterozy-
gous db/m mice treated with saline; group II (db/db +
vehicle) comprised six db/db mice treated with saline;
group III (db/db + silibinin) included six db/db mice
treated with silibinin (20 mg/Kg i.p. injection, daily). At
12 weeks of age, after an overnight fast, animals were
anesthetized and sacrificed; blood, aorta and liver sam-
ples were obtained for further analysis.
Biochemical analyses
Blood glucose was measured by Accu-chek (Roche Diag-
nostics, Milan, Italy). Serum insulin was determined
using an automated enzyme immunoassay analyzer from
Tosoh (Tokio, Japan). HOMA-IR was calculated as fol-
lows: [fasting glucose (mmol/L) × fasting insulin (mU/
L)]/22.5. Plasma and tissue ADMA concentration was
determined by using a commercially available enzyme-
linked immunosorbent assayk i t( D L DD i a g n o s t i k a
GmbH, Hamburg, Germany) according to the manufac-
turer’s instructions.
Vasomotor tone
Aortas were immersed in physiological salt solution
(composition, mmol/L: NaCl, 118; KCl, 4.6; NaHCO3,
25; MgSO4,1 . 2 ;K H 2PO4,1 . 2 ;C a C l 2,1 . 2 ;g l u c o s e ,1 0 ;
EDTA, 0.025; pH 7.4 at 37°C), dissected out of sur-
rounding connective tissue, cut in segments (2 mm
length) and mounted in a wire myograph (610 M, Dan-
ish Myo Technology, Aarhus, Denmark), by using 40
μm-diameter stainless steel wire, for isometric record of
contractile force. After mounting, each preparation was
equilibrated unstretched, for 30 min, in physiologic salt
solution, maintained at 37°C and aerated with a gas
mixture 95% O2 -5 %C O 2. The normalized passive rest-
ing force and the corresponding diameter were then
determined for each preparation from its own length-
pressure curve, according to Mulvany and Halpern [26].
Contractile responses were recorded into a computer,
by using a data acquisition and recording software
(Myodaq and Myodata, Danish Myo Technology). After
normalization and 30-min equilibration in physiological
solution, the preparations were constricted with isotonic
depolarizing KCl solutions, in which part of NaCl had
been replaced by an equimolar amount of KCl (compo-
sition, mmol/L: NaCl, 22.6; KCl, 98.8; NaHCO3,2 5 ;
MgSO4,1 . 2 ;K H 2PO4,1 . 2 ;C a C l 2,1 . 2 ;g l u c o s e ,1 0 ;
EDTA, 0.025, pH 7.4 at 37°C). After washout and 30-
min recovery, the preparations were exposed to cumula-
tive concentrations of phenilephrine (PE, 1 nmol/L - 1
μmol/L). Once the vasoconstriction to PE had reached
steady state, cumulative concentrations of acetylcholine
(ACh, 1 nmol/L - 1 μmol/L) were added to the organ
chamber. Relaxing responses were expressed in percen-
tage of pre-existing contractile tone, induced by PE.
After wash out and 30 min recovery, preparations were
exposed to 5 nmol/L PE, which induced a negligible (<
2% of K
+100) vasoconstriction in lean, but a stronger
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+100); once PE-induced tone
had reached a steady state, preparations were challenged
with cumulative concentrations of asymmetric N
G,N
G-
dimethyl-L-arginine (ADMA, 300 nmol/L - 300 μmol/
L). Preparations were then further constricted by 1
μm o l / LP Ei nt h ep r e s e n c eo f1 0 0μmol/L N
G-nitro-L-
arginine (LNNA), once PE-induced tone had reached a
steady state, preparations were challenged with cumula-
tive concentrations of sodium nitroprusside (SNP, 1
nmol/1 L - 1 μmol/L), to assess endothelium-indepen-
dent vasodilatation. PE, ACh, SNP, LNNA and ADMA
were from Sigma (St. Louis, MO, U.S.A.); 10 mmol/L
stock solutions were prepared in water and further
diluted in physiological salt solution as required, except
for ADMA, which was dissolved in water as 30 mmol/L
stock solution. Concentration-response curves to
vasoactive agonists were plotted as response (for vaso-
constrictors, in % of vasoconstriction induced by KCl in
the same arteries; for vasodilators in % of residual tone)
against log molar concentration of drug. Each set of
data points was curve-fitted by a non-linear regression,
best-fit, sigmoid dose-response curve with no con-
straints, with the use of Graph Pad Prism (Graph Pad
Software, San Diego, CA). Pharmacological parameters
(concentration producing 50% of maximum effect or
EC50 and maximum effect or Emax) were calculated from
these non-linear fits. Each curve represents 12 prepara-
tions from 6 different mice.
Statistical analysis
Statistics were aided by Graph Pad Prism. All results
were expressed as mean ± standard error of mean (S.E.
M.). P values less than 0.05 were considered significant.
Biochemical data were analyzed by one-way ANOVA
with Bonferroni Post-Hoc analysis. Concentration-
response curve from isolated aortas were compared by
two-way ANOVA.
Results
Metabolic parameters
All db/db mice weighted more than lean controls at
week 8, before starting the treatment; silibinin adminis-
tration did not significantly change body weight or food
intake (data not shown). Untreated db/db were insulin
resistant, as shown by HOMA-IR; silibinin decreased
fasting glucose and insulin, reversing insulin resistance
(Table 1).
Plasma, aorta and liver ADMA levels
Plasma ADMA levels were higher in db/db than in db/
m (Figure 1A). Silibinin reduced plasma ADMA in db/
db to a level lower than in db/m animals. These differ-
ences in ADMA levels were even more pronounced in
aorta, where, again, ADMA was higher in db/db
compared to db/m and was reduced by silibinin in db/
db mice, by more than 50% (Figure 1B). Liver ADMA
was slightly lower in db/db as compared to lean con-
trols, although the difference was not statistically signifi-
cant, whereas silibinin led to raised ADMA in hepatic
tissue (Figure 1C). Plasma and aorta ADMA levels were
positively correlated (Figure 1D); by contrast, liver
ADMA was inversely correlated with both plasma and
aorta ADMA concentrations (Figure 1E).
Vascular tone
Contractile tone induced by high K
+ was higher in aorta
preparations from db/db than in db/m mice and was
not influenced by silibinin treatment (db/m + vehicle,
3.42 ± 0.25 mN/mm; db/db + vehicle, 4.33 ± 0.35 mN/
mm; db/db + silibinin, 4.36 ± 0.27 mN/mm; db/m +
vehicle versus all db/db, P < 0.05).
Vasoconstriction to PE, either expressed as raw values
(mN/mm, not shown) or normalized in % of K
+-induced
contraction (Figure 2A and Table 2) was also higher in
db/db; in particular concentration-contraction curve to
PE was displaced to the left in db/db mice, in a parallel
manner. Vasoconstriction to PE was not modified by
silibinin administration. Endothelium-dependent vasodi-
latation to ACh and, to a less extent, endothelium-inde-
pendent vasodilatation to SNP were lower in db/db
mice as compared to lean animals (Figure 2B, C and
Table 2); vasodilatation to ACh was significantly
increased by silibinin, whereas endothelium-independent
vasodilatation to SNP was not modified by the treat-
ment. In vitro challenge with ADMA induced a stronger
contractile tone in aorta from db/db mice than in db/m
( F i g u r e2 D ) ;o fn o t e ,t h et o n ei n d u c e db ya p p l y i n g
ADMA in vitro in aorta from db/db mice, was not influ-
enced by in vivo silibinin.
Discussion
Endothelial dysfunction plays a pivot role in the initia-
tion of the cascade of events leading to CVD [3].
Table 1 Biometric and biochemical parameters
db/m +
vehicle
db/db +
vehicle
db/db +
silibinin
8-weeks weight
(g)
22.5 ± 0.5 33.0 ± 2.2* 32.5 ± 2.7*
12-weeks weight
(g)
25.6 ± 1.2 38.4 ± 1.8* 36.8 ± 1.9*
Blood glucose
(mg/dL)
68.2 ± 7.6 220.8 ± 40.2** 112.7 ± 22.8
†
Serum insulin
(mU/L)
6.8 ± 1.2 10.3 ± 0.8** 7.5 ± 1.1
†
HOMA-IR 1.1 ± 0.2 5.6 ± 0.5** 2.1 ± 0.3
††
*P < 0.05, **P < 0.01 versus db/m + vehicle,
†P < 0.05,
†† P < 0.01 versus db/
db + vehicle.
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Figure 1 Plasma, aorta and liver ADMA levels. (A) Plasma ADMA was higher in db/db mice than lean controls and was significantly
decreased by silibinin administration. (B) Aorta ADMA was similarly higher in untreated db/db mice and was markedly decreased in mice treated
with silibinin. (C) Liver ADMA was increased in the silibinin group. (D) Plasma and aorta ADMA levels exhibited a positive correlation (r2=0.95,
P<0.0001). (E, F) Liver ADMA levels were inversely related to both plasma ADMA (r2=0.66, P<0.01) and aorta ADMA (r2=0.69, P<0.01). **P < 0.01
versus db/m + vehicle; ††P < 0.01 versus db/db + vehicle.
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ber of pathological conditions associated with endothe-
lial dysfunction, including diabetes, dyslipidemia and
obesity [9,10]. In type 2 diabetes, ADMA levels are asso-
ciated with macrovascular diseases independently of tra-
ditional cardiovascular risk factors [15] and ADMA
pathway has been proposed as a link between inflamma-
tion and endothelial dysfunction [27].
In this study, we report, for the first time, the associa-
tion of ADMA levels with endothelial dysfunction in
db/db mice and demonstrated that silibinin, a world-
wide-used flavolignan from milk thistle, favorably
impacts on ADMA levels and improves endothelial
dysfunction. We found that db/db mice exhibit, both in
plasma and aorta, ADMA levels higher than db/m mice.
In silibinin-treated db/db, the substantial reduction of
plasma and vascular ADMA is associated with the
improvement of insulin resistance; this is in accordance
with data in humans indicating that serum ADMA pre-
dicts the degree of insulin sensitivity [16]. Interestingly,
circulating ADMA is not related to brachial artery-flow
mediated dilatation in patients with type 1 diabetes [28].
The pathways involved in the beneficial effect of silibi-
nin on insulin resistance are not known; however, a pos-
sible explanation for the decrease in blood glucose levels
in treated animals may be the inhibition of liver
CD B
CD
db/m
db/m
db/db + vehicle**
db/m
A
db/db + silibinin**
db/m + vehicle
db/m + vehicle
db/db + vehicle**
db/db + silibinin**††
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**
** **
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Figure 2 Vasomotor responses in isolated aorta. (A) Vasoconstriction to phenilephrine (PE); (B) vasodilatation to acetylcholine (ACh); (C)
vasodilatation to sodium nitroprusside (SNP); (D) vasoconstriction to asymmetric N
G,N
G-dimethyl-L-arginine (ADMA). Vasoconstriction is
expressed in % of high K
+-induced tone in the same preparation; vasodilatation is expressed as residual tone in % of PE-induced preconstriction.
**P < 0.01 versus db/m + vehicle;
††P < 0.01 versus db/db + vehicle.
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lin signaling and ADMA homeostasis is poorly under-
stood at present; data obtained in endothelial cells
suggest that insulin and adiponectin modulate the activ-
ity of DDAH [30]. Of note, DDAH gene variants influ-
ence the risk of diabetes and its complications [31].
Vascular endothelium is not the only contributor to
regulation of plasma ADMA levels [12], and the role of
other tissues and organs in ADMA metabolism remains
to be elucidated. Interestingly, in this study we found
not only a positive correlation between plasma and vas-
cular ADMA, but also an inverse correlation between
liver and both plasma and aorta ADMA. The molecular
basis for the observed correlations is not clear; we can
speculate that the increase of hepatic ADMA in db/db
mice induced by silibinin may involve the system of y
+
carriers of the cationic amino acid family, which has
been shown to play a relevant role in the clearance of
dimethylarginines in the liver [32]. In this respect,
further studies in mice with diet-induced obesity/dia-
betes might be helpful. Similarly, the role of kidney in
ADMA clearance should also be elucidated, although
previous findings, showing that ADMA clearance is con-
served in nephrectomized mice [33], indicate that it may
be less substantial.
Our observation of impaired endothelium-dependent
vasodilatation to ACh in db/db mice is consistent with
previous reports [19-24]. Moreover, we found that
endothelium-dependent vasodilatation of isolated aorta
to ACh was improved by silibinin in db/db mice; because
silibinin reduced ADMA levels in aorta, the subsequent
reduction of NOS inhibition by ADMA may, at least in
part, account for the observed improvement of endothe-
lium-dependent vasodilatation. Surprisingly, despite the
effect on aorta ADMA levels, silibinin did not modify in
vitro vascular responsiveness to either PE or high K
+.
Enhanced vasoconstriction to a-adrenergic stimulation
has been attributed to reduced basal nitric oxide produc-
tion in db/db mice [19]; since silibinin did not change the
concentration-response curve to PE, additional mechan-
isms, other than increase in ADMA levels, must be pos-
tulated for the reduced basal NO production in db/db
mice; among them, free radical generation has been
documented and may play an important role. Increased
generation of oxygen free radicals is supposed to increase
NO scavenging (with production of reactive species such
as peroxynitrite), thereby reducing the vasodilator effec-
tiveness of endogenous or exogenous (from NO-donor
drugs) NO. In accordance with this hypothesis, endothe-
lium-independent vasodilatation to SNP has also been
s h o w nt ob er e d u c e di nd b / d bm i c e[ 2 3 ] .H e r ew ec o n -
firm this latter issue, showing a slight, but significant, dis-
placement to the right of the concentration-response
curve to SNP in db/db mice. Because SNP is a NO-
donor, reduced sensitivity to SNP implies reduced sensi-
tivity to NO and/or increased NO scavenging in db/db
vessels. Of note, the reduced responsiveness to SNP in
db/db mice was not changed by silibinin treatment. Such
a reduced sensitivity to NO in db/db vessels may also, at
least in part, account for the reduced vasodilatation to
ACh; however, the fact that silibinin improved the
response to ACh, while not changing the response to
SNP, would indicate that in silibinin-treated animals
ACh-induced NO production was increased, possibly
because endogenous ADMA was reduced, leading to
increased NOS activity. Finally, when applied in vitro,
ADMA elicited the same contractile response in the two
groups of db/db mice, regardless of the treatment, sug-
gesting that silibinin in vivo may inhibit ADMA produc-
tion rather than enhance its vascular degradation.
Conclusions
In conclusion, in this study we showed that plasma
ADMA levels are increased in db/db animals similarly
to diabetic patients. The increased ADMA levels are
Table 2 Pharmacological parameters of vasomotor
responses to phenilephrine (PE), acetylcholine (Ach),
sodium nitroprusside (SNP) and asymmetric N
G,N
G-
dimethyl-L-arginine (ADMA) in isolated aorta
PE
pD2 EC50 (nmol/L) Emax (% K
+)
db/m + vehicle 7.27 ± 0.11 53.7 (32.1-89.7) 126.0 ± 7.0
db/db + vehicle 7.74 ± 0.10** 18.3 (11.3-29.9) 122.3 ± 5.0
db/db + silibinin 7.66 ± 0.08** 21.7 (15.3-30.7) 122.6 ± 3.7
ADMA
pD2 EC50 (μmol/L) Emax (% K
+)
db/m + vehicle 3.36 ± 1.76 440 (0.1-10
6) 65.6 (± 154)
db/db + vehicle 4.48 ± 0.36** 32.8 (5.8-188) 69.6 ± 12.0
db/db + silibinin 4.51 ± 0.40** 30.1 (4.8-194) 71.2 ± 12.6
ACh
pD2 EC50 (nmol/L) Emax(% tone)
db/m + vehicle 7.54 ± 0.12 28.8 (16.7-49.5) 35.7 ± 2.5
db/db + vehicle 6.74 ± 0.15** 183 (90.2-372) 62.1 ± 2.1**
db/db + silibinin 6.89 ± 0.12** 130 (74.9-224) 43.7 ± 2.8
††
SNP
pD2 EC50 (nmol/L) Emax(% tone)
db/m + vehicle 7.97 ± 0.04 10.1 (8.8-12.9) 9.4 ± 1.0
db/db + vehicle 7.45 ± 0.06** 35.7 (26.5-48.0) 16.7 ± 1.7*
db/db + silibinin 7.56 ± 0.05** 27.7 (21.7-35.3) 11.8 ± 1.5
Pharmacological parameters are from non linear regression; pD2 is the
negative logarithm of the concentration producing 50% of the maximum
effect, EC50 is the concentration producing 50% of maximum effect (95%
confidence limits are given in parenthesis), Emax is the maximum effect
(vasoconstriction to PE or ADMA in % of vasoconstriction evoked in the same
preparations by 100 mmol/L K
+; vasodilatation to ACh or SNP as % of residual
tone). Statistical comparisons were made on the whole curves by two-way
ANOVA; n = 12 preparations from 6 mice in each group; *P < 0.05, **P < 0.01
versus db/m + vehicle,
††P < 0.01 versus db/db + vehicle.
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treatment reversed plasma and aorta ADMA increase
and improved both endotheliald y s f u n c t i o na n di n s u l i n
resistance. These pharmacological properties of silibinin
are of potential clinical interest given its favorable safety
profile.
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